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Membrane omega-3 fatty acids 
modulate the oligomerisation 
kinetics of adenosine A2A and 
dopamine D2 receptors
Ramon Guixà-González1,*, Matti Javanainen2,*, Maricel Gómez-Soler3, Begoña Cordobilla4, 
Joan Carles Domingo4, Ferran Sanz1, Manuel Pastor1, Francisco Ciruela3,5, Hector Martinez-
Seara2 & Jana Selent1
Membrane levels of docosahexaenoic acid (DHA), an essential omega-3 polyunsaturated fatty acid 
(ω-3 PUFA), are decreased in common neuropsychiatric disorders. DHA modulates key cell membrane 
properties like fluidity, thereby affecting the behaviour of transmembrane proteins like G protein-
coupled receptors (GPCRs). These receptors, which have special relevance for major neuropsychiatric 
disorders have recently been shown to form dimers or higher order oligomers, and evidence suggests 
that DHA levels affect GPCR function by modulating oligomerisation. In this study, we assessed the 
effect of membrane DHA content on the formation of a class of protein complexes with particular 
relevance for brain disease: adenosine A2A and dopamine D2 receptor oligomers. Using extensive 
multiscale computer modelling, we find a marked propensity of DHA for interaction with both A2A 
and D2 receptors, which leads to an increased rate of receptor oligomerisation. Bioluminescence 
resonance energy transfer (BRET) experiments performed on living cells suggest that this DHA effect 
on the oligomerisation of A2A and D2 receptors is purely kinetic. This work reveals for the first time that 
membrane ω-3 PUFAs play a key role in GPCR oligomerisation kinetics, which may have important 
implications for neuropsychiatric conditions like schizophrenia or Parkinson’s disease.
Several studies have found substantially lower levels of docosahexaenoic acid (DHA) in the brains of individuals 
with mental1 or neurological disorders2,3. DHA is an omega-3 polyunsaturated fatty acid (ω-3 PUFA) of 22 car-
bons and 6 double bonds (22:6n3) that has been shown to be essential for the development4 and maintenance of 
adequate brain function5,6. The high levels of DHA found in specialized cell platforms such as retinal rod outer 
segments or neuronal cells seem to provide these membranes with particular biophysical properties such as an 
increased lipid mobility and amenability to deformation7,8. Furthermore, DHA is able to affect the lateral organ-
ization of cell membranes through the formation of the so-called anti-raft domains which promote the function 
of specific proteins9. The unique biophysical properties of DHA along with its potential neuroprotective effects5,10 
have made DHA a promising candidate against certain neurodegenerative disorders11,12.
In addition, recent studies have shown that the lipid composition of cell membranes can modulate the func-
tion of key membrane proteins such as G protein-coupled receptors (GPCRs)13,14. GPCRs are involved in a wide 
range of diseases and are particularly important for several major psychiatric disorders15. Therefore, understand-
ing the role of the membrane environment on the dynamics and function of GPCRs has become a research 
priority in this field. For instance, the high amount of DHA present in retinal rod cell membranes is known to 
modulate the function of rhodopsin, a widely studied GPCR specific to these cells, by increasing lateral diffusion 
and thus the efficiency of G-protein coupling16. The modulatory effect of DHA on rhodopsin was first described 
by Mitchell et al.17 and has since been further studied using experimental16,18 and computational19,20 methods. 
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DHA is therefore known to influence the biology of rhodopsin and could potentially modulate other GPCRs in 
other DHA-enriched tissues such as the brain4.
However, an additional level of complexity adds to the overall picture of DHA–GPCR modulation: GPCRs 
have recently been found to function as dimers or higher order oligomers, and despite initial controversy, the 
existence and relevance of GPCR oligomerisation has gained broad acceptance21. Interestingly, impaired crosstalk 
between specific GPCR heteromers seems to affect GPCR signalling resulting in defective neurotransmission and 
brain dysfunction22,23. Therefore, GPCR heteromers are nowadays desired drug targets24,25 and have inspired new 
drug strategies such as the use of heterobivalent or dual acting ligands26,27. In particular, the study of adenosine 
A2A and dopamine D2 receptors, which have been shown to form dimers28,29 and oligomers30,31 is becoming highly 
relevant in neuropsychiatry32,33. A specific balance of membrane A2A and D2 oligomers is thought to be behind the 
altered signalling cascade observed in Parkinson’s disease and schizophrenia34,35.
Given the importance of GPCR oligomerisation and membrane DHA in brain dysfunction, the question that 
naturally arises is do membrane lipids affect GPCR oligomerisation? It seems possible that this is the mecha-
nism through which DHA modulates GPCR biology, and subsequently neurological disease processes. In this 
study we compared the effects of high and low levels of DHA on the homo- and heteroligomerisation of A2A and 
D2 receptors. We performed molecular dynamics (MD) simulations of the self-assembly process of A2A and D2 
receptors simultaneously embedded in multicomponent model membranes reaching an exceptionally long total 
simulation time of nearly 4 ms. We then compared the effect of high and low levels of membrane DHA on protein 
aggregation and studied the particular affinity between this lipid and A2A and D2 receptors. We complemented 
MD simulations with bioluminescence resonance energy transfer (BRET) experiments in living cells in order to 
study the effect of DHA on the degree of oligomerisation in the steady state.
Receptor oligomerisation is a dynamic process comprising receptor association and dissociation events. 
Unfortunately, no single experimental approach can capture this complex process combining high-resolution 
conditions at the required time scale. Therefore, in this paper we focus on the molecular details behind fast 
events of receptor oligomerisation, namely receptor association (microsecond time scale), using all-atom and 
coarse-grained MD simulations. In addition, we use BRET experiments in living cells to explore receptor asso-
ciation/dissociation events at longer time scales needed to achieve equilibrium (millisecond time scale). Our 
results suggest for the first time that GPCR oligomerisation kinetics can be modulated by membrane ω-3 PUFAs. 
The concentration of DHA present in the healthy brain provides membranes with fluidity required for rapid 
receptor diffusion. Additionally, DHA seems to foster oligomerisation by promoting membrane phase separa-
tion. BRET experiments do not, however, find differences in the oligomerisation state between DHA-enriched 
and DHA-depleted membranes in the steady state suggesting that the effect of DHA on protein oligomerisation 
is mainly a kinetic one. These results provide a molecular link between membrane lipid composition and the rate 
of GPCR oligomerisation, which could help in the development of new strategies to treat major neurological 
disorders.
Methods
Coarse-grained MD simulations. We performed a complete set of coarse-grained (CG) MD simulations to 
study the oligomerisation of A2A and D2 receptors in membranes of various compositions using the Martini force 
field36,37. First, a small patch (i.e. approximately 11 × 11 nm2 in the membrane plane) containing two receptors 
separated from each other (i.e. distance between the positions of their centres of mass (COM) > 9 nm) was cre-
ated. CG models of A2A and dopamine D2 receptors were built based on the inactive crystal structures PDB:3EML 
and PDB:3PBL, respectively. The native sequence of these structures was used. Unresolved residues were added 
and the intracellular loop 3 was omitted. Subsequently, the content of this patch was independently replicated to 
create larger systems. In order to study protein aggregation, we considered two receptors to be in direct contact 
if the distance between the positions of their COMs was < 4.2 nm. Lipid-mediated contacts are also accounted 
for, as long as the cut-off distance criteria is met. Detailed information of each system and thorough building, 
simulation and analysis protocols can be found in the Supporting Information (SI). Initially, we simulated nine 
A2A and nine D2 receptors embedded38 in two model membranes of different lipid composition. These composi-
tions aimed to reflect the general brain lipid profiles previously observed in post-mortem studies of healthy and 
diseased individuals1–3. Briefly, the healthy-like (rich in DHA) and diseased-like (poor in DHA) models contained 
21% and 6% of a DHA-phospholipid (i.e. SDPC, 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine), 
respectively; the diseased-like model was compensated with a higher fraction of saturated lipids (see Table 1). 
SDPC contains mixed chains (C22:6 (DHA) and C18:0), so these SDPC levels translate into a DHA content of 
11% and 3% over total fatty acids, respectively (see Table 1). 33% cholesterol was also present in both membranes. 
Three replicas, each 60 μ s long, were simulated for both compositions. Additionally, other similar systems were 
simulated to support the findings of this study. All these simulations, totalling to almost 4 ms, are summarized 
in Table S1 with their compositions given in Tables S2 and S3. We report all CG-MD simulation using effec-
tive times, a standard 4-fold speed-up conversion factor that accounts for the loss of friction in the MARTINI 
CG-MD model36.
BRET experiments. HEK-293T cells were transiently transfected with a constant amount (0.3 μ g) of A2A
Rluc 
and increasing amounts of plasmid encoding D2
YFP, namely from 0.25 to 3.7 μ g (see section 1.6 in the SI). The 
cDNAs encoding A2A
Rluc, D2
YFP and CD4YFP were previously described in refs 39,40. Both fluorescence and lumi-
nescence signals from each sample were measured prior to experiments to confirm equal expression of the Rluc 
construct while monitoring the increase in YFP expression. Cells were then treated with DHA 200 μ M for 48 h in 
the presence of adenosine deaminase (ADA, 0.2 U/mL) to remove any trace of adenosine from the culture 
medium, and were rapidly washed twice with phosphate-buffered saline, detached and re-suspended in the same 
buffer (see section 1.6 in the SI). This treatment resulted in the rise of DHA content from 0.99 ± 0.03% to 
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6.49 ± 0.32% (see section 1.6 in the SI). Triplicate samples of cell suspension (20 μ g protein) were distributed in 
black bottom 96-well black microplates or white bottomed 96-well white microplates (Fisher Scientific, Madrid, 
Spain) for fluorescence or BRET experiments, respectively. For BRET measurements, colenterazine-h substrate 
(NanoLight Technology, Pinetop, Arizona, USA.) was added to a final concentration of 5 μ M. BRET readings 
were performed at 1 and 10 min using the POLARstar Optima plate reader (BMG Labtech, Durham, NC, USA). 
This plate reader allows detection and sequential integration of both luminescence (Rluc) and fluorescence (YFP) 
signals by two filter settings: 440–500 nm and 510–560 nm windows to detect 485 nm (Rluc, donor) and 530 nm 
(YFP, acceptor) signals, respectively. The BRET ratio (i.e. the fluorescence signal over the luminescence signal) 
was defined as described previously39 and measured in 4 independent experiments where cells were treated with 
DHA. The values of BRETmax (i.e. the maximal signal reached at saturation) and BRET41 (i.e. BRET ratio giving 
50% of the BRETmax) were also calculated as in ref. 39. The statistical assessment of BRETmax and BRET41 values 
across experiments was performed using a paired t test comparing DHA-treated versus non-treated cells. An 
equivalent BRET protocol was employed for receptor homomerisation experiments, as described in ref. 28.
All-atom simulations. The CHARMM3642, CHARMM36c43 and CHARMM2744 force fields were used to 
represent lipids, cholesterol and proteins, respectively. The adenosine A2A receptor was embedded into an equil-
ibrated healthy-like membrane patch (see Table 1 and Table S4). A production run of 4 μ s in the was performed 
using the ACEMD simulation package45. A detailed description of the construction, simulation protocols, and 
analyses is provided in section 1 of the SI.
Results
ω-3 PUFA increases oligomerisation in CG-MD simulations. We quantified protein aggregation in 
healthy-like and diseased-like membranes by analysing the number of protein–protein contacts consolidated 
during the simulation (see Table S1 for number and length of simulations). First protein–protein contacts already 
occur within 5–10 μ s and they seem rather unspecific. To make sure that mostly stable contacts are quantified, we 
analysed the last 20 μ s of the 60 μ s simulations. Analysis of all simulations shows that protein aggregation is signif-
icantly enhanced (i.e. ~20% higher) in healthy-like conditions (high DHA). Specifically, the mean number of pro-
tein–protein contacts per monomer is 1.48 ± 0.06 and 1.20 ± 0.08 in healthy-like (high DHA) and diseased-like 
(low DHA), respectively. This finding suggests that DHA plays an important role in the oligomerisation kinetics 
of A2A and D2 receptors. It is worth noting though that due to the coarse level of description of the CG model and 
the restraints applied to preserve protein tertiary structure (see section 1.1 in the SI), our CG-MD simulations 
cannot capture conformational changes related to receptor activation.
DHA treatment does not increase the amount of oligomers at equilibrium in living cells. To 
study the effect of DHA on the steady-state kinetics of D2 and A2A receptor oligomerisation, BRET experiments 
were carried out in living cells. In a first step, we demonstrated adequate incorporation of DHA into HEK-293T 
cell membranes (see section 1.6 in the SI). Then, we further investigated the role of membrane DHA in A2A and 
D2 homo- and heteromerisation. BRET is a powerful technique for characterizing GPCR oligomers46 in the steady 
state albeit an accurate interpretation of the results is needed, as recently illustrated by Lan et al.47. In particular, 
BRET has been already useful for comparatively study the effect of certain modulators on GPCR oligomerisa-
tion41,48,49. In our experiments, a positive and saturable BRET signal for the transfer of energy between the accep-
tor A2A
Rluc and the donor D2
YFP constructs was observed (Fig. 1a) in cells co-transfected with a constant amount of 
A2A
Rluc and increasing concentrations of D2
YFP. In addition, since the control receptor pair, A2A
Rluc and CD4YFP, led to 
the typical quasi-linear curve39,40, the specificity of the saturation (hyperbolic) assay for the −A D2A
Rluc
2
YFP pair 
could be established. These results corroborate previous results indicating that A2A and D2 receptors form consti-
tutive heterodimers in living cells39.
To assess the effect of DHA on the A2A − D2 heteromerisation (i.e. BRET signal), we performed 4 independent 
BRET titration experiments in the presence and absence of a saturating concentration of DHA (200 μ M) (Fig. 1). 
Phospholipid (tails) Healthy (%) Diseased (%)
DPPC (diC16:0) 21 33
DSPC (diC18:0) 7 15
DOPC (diC18:1) 15 11
SDPC (C22:6/C18:0) 21 6
SM (C18:1/C16:0) 36 36
Fatty acid Healthy (%) Diseased (%)
C16:0 39 51
C18:0 43 41
C18:1 7 5
C22:6 11 3
Table 1.  Phospholipid and fatty acid compositions of healthy- and diseased-like model membranes used 
in all simulations. Both membranes also contained 33% cholesterol. Abbreviations signify 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleyl-sn-
glycero-3-phosphocholine (DOPC), 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (SDPC) and 
sphingomyelin (SM).
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Interestingly, as demonstrated by the large p values (i.e. p > 0.05) (Fig. 1b), preincubation with DHA for 48 h did 
not increase the maximum BRET signal (BRETmax) in the experiments performed with −A D2A
Rluc
2
YFP 
co-transfected cells. Similarly, DHA treatment did not have a systematic effect on the amount of acceptor-labelled 
receptor (D2
YFP) needed to reach 50% of the maximal BRET signal (BRET50) (see Fig. 1c). Therefore, DHA treat-
ment was not found to affect the amount of heteromers present in steady-state conditions. Similarly, the number 
of A2A − A2A or D2 − D2 homodimers are not affected by membrane DHA, as shown in Fig. S23.
Overall, the computational results suggest that DHA treatment increases the kinetics of A2A − D2 heteromeri-
sation. Notably, additional simulations matching the exact content of DHA present in the experiments (see Table 
S1, Section 2.14 and Fig. S20) confirm an increased oligomerisation kinetics in the presence of higher levels of 
DHA. In contrast, the presence of this fatty acid does not regulate the amount of oligomers present in equilibrium, 
as shown by our BRET experiments.
Polyunsaturated lipids avidly surround A2A and D2 receptors in CG-MD and all-atom simula-
tions. To unlock the reasons that govern DHA-induced faster aggregation kinetics, MD simulations were 
employed to further characterize the affinity between DHA and A2A and D2 protomers. As shown in the CG-MD 
simulations (see Movie S1), DHA-enriched phospholipids (i.e. SDPC) display a striking preference for interaction 
with A2A and D2 receptors. In fact, this video clearly shows how a shell of this lipid surrounds GPCR monomers 
virtually from the beginning of the simulation, and how GPCR oligomers are still surrounded by SDPC molecules 
by the end of the simulation. To support these observations, we calculated the radial distribution function of each 
lipid type around the A2A (see Fig. 2) and D2 (see Fig. S4) receptors. This analysis confirms that during CG-MD 
simulations the first solvation shell around the protein is primarily populated by phospholipids with DHA tails 
(SDPC). This DHA shell cannot completely form in the diseased-like systems (low DHA).
To validate this strong interaction between DHA and the receptors in the CG-MD simulations, we com-
plemented these simulations using all-atom molecular dynamics of A2A embedded in a healthy-like membrane 
system (see Table 1 and Table S4). A final snapshot of the all-atom simulation at 4 μ s (Fig. 3, right) confirms that 
unsaturated phospholipids, namely DOPC and SDPC, have a strong preference for solvation of the protein. In 
agreement with previous simulations19, DHA does not exhibit affinity for a particular helix but rather solvates the 
A2A receptor in a general fashion (see Fig. S6). Nevertheless, more atomistic simulations (i.e. more statistics) of 
both receptors are needed to draw consistent conclusions in this respect. To quantitatively assess this effect, we 
calculated the mean number of contacts per atom between unsaturated tails and the protein and compared this 
value with that for saturated tails (see Section 1.4.1 in the SI). The proportion of lipid–protein contacts between 
unsaturated tails with respect to saturated ones clearly grows during the simulation (see Fig. 4). Specifically, DHA 
tails (i.e. sn-2 chain of SDPC) display the highest growth rate (see Fig. 4) and confirm the tendency of this fatty 
acid to interact with the protein. In addition, the contact ratio of SDPC over DOPC remains equilibrated (i.e. 
around 1) until the end of the simulation, when, proportionally more SDPC is in contact with the protein (see 
Figs S5 and 4). These results imply that, as we observe in Fig. 3, DHA gradually populates the closest lipid shell 
around the A2A during the all-atom simulation.
In addition, as shown in CG-MD simulations (Movie S1), an SDPC shell seems to act as a lubricating film in 
many of the dimer and oligomer formation events. It is tempting to suggest that the high affinity between DHA 
and GPCRs is responsible for the mechanism which fosters the oligomerisation kinetics of A2A and D2 protomers. 
This effect might, however, not alter the number of oligomers present under equilibrium, as suggested by the 
BRET experiments.
DHA accelerates the kinetics of GPCR oligomerisation. We performed an in-depth characterization 
of the protein aggregation behaviour observed in CG-MD simulations. The final snapshots of these CG-MD 
Figure 1. Effect of DHA on the amount of A2A–D2 heteromerisation in cellular steady state with low 
(red) and high (blue) DHA content. (a) shows representative BRET saturation curves, where each point 
measurement was performed in triplicate. BRET ratios (×1000) are in mBRET units (mBU). Error bars show 
the SEM. (b,c) columns show, respectively, the BRETmax and BRET50 results of 4 independent experiments with 
low (red) and high (blue) amounts of DHA. These results were compared by a paired t test and the p values are 
shown.
www.nature.com/scientificreports/
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Figure 2. Probability density (i.e. radial distribution function, g(r)) of lipids around the center of mass (COM) 
of the A2A receptor embedded in healthy- (high DHA, (a)) and diseased-like (low DHA, (b)) model membranes 
in CG-MD simulations. y axis represent g(r) (arbitrary units) and x axis the distance to the protein COM in nm. 
The radial distribution function of SM heavily overlaps with the rest of saturated lipids (i.e. DPPC and DSPC). 
Radial distribution functions for the D2 receptor are shown in Fig. S4.
Figure 3. Initial and final (4 μs) snapshots of the all-atom simulation of the A2A receptor embedded in 
a healthy-like membrane (high DHA). Protein helices are depicted in blue and loops in white. Unsaturated 
phospholipids (SDPC and POPC) are drawn as yellow surfaces with dark grey spheres corresponding to other 
lipid types. Water and ions are omitted for clarity.
www.nature.com/scientificreports/
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simulations, shown in Fig. 5, indicate that protein oligomers tend to form extended rather than compact struc-
tures in both healthy-like and diseased-like environments. Within these oligomers, protomers establish mostly 
1- (dimers) or 2-contacts (trimers) and only rarely 3-contacts (tetramers) with other protomers. Such array-like 
disposition has already been described in previous CG-MD simulations of GPCRs50,51. To confirm the behaviour 
of protein oligomers at longer timescales, we extended one of the simulations (i.e. initial snapshot shown in 
Fig. 5a) up to 260 μ s. The final snapshot of this extended simulation, shown in Fig. S7d, displays an extended-like 
and short-branched arrangement of the protein oligomer where nearly all protomers form at least one protein–
protein contact. It is worth noting that during these 60–260 μ s, the number of protein–protein contacts generally 
remained between one and two contacts per protomer (see Fig. S7a–d and Section S2.5).
The evolution of protein aggregation significantly varied between healthy- and diseased-like systems, as shown 
by the number of protein–protein contacts over time depicted in Fig. 6. This figure shows that A2A and D2 dimers 
form significantly quicker in high-DHA (Fig. 6, left column) systems when compared to low-DHA ones (Fig. 6, 
right column). To provide more statistical support for this finding, we performed 5 additional shorter replicas 
(see Table S1 for number and length of simulations) for both membrane compositions, obtaining a similar ten-
dency (see Fig. S9). As shown in Fig. 7, the mean number of protein–protein contacts per protomer in these short 
replicas begin to deviate during the 4–8 μ s interval of the simulation, as protomers embedded in healthy-like 
model membranes were able to engage in twice as many protein–protein contacts compared to diseased-like 
membranes. Therefore, increasing levels of membrane ω-3 PUFAs (i.e. DHA) seems to speed up GPCR oligom-
erisation by promoting a higher numbers of protein–protein contacts in shorter times. Two possible mechanisms 
might explain this tendency. First, the presence of DHA might enhance the rate of oligomerisation partner search 
through increased lateral diffusion. Second, oligomerisation might be fostered by the merging of the lubricating 
DHA shells of individual receptors. This process is possibly driven by the tendency of the membrane to separate 
into DHA-enriched and DHA-depleted domains. Likewise, the latter process competes with the propensity of 
DHA to interact with the receptors.
In the time scale of our simulations, as previously described in similar studies50,52,53, GPCR complexes do 
not tend to disrupt once they form. As a result, the initial arrangement of protomers likely determines the 
nature of the predominant interaction found at the end of the simulation (i.e. heteromers versus homomers). 
For example, at the end of the simulation (see Fig. 5), heteromers account for a major fraction of contacts in 
healthy and diseased-like systems. To further characterize this observation we performed new simulations 
using different initial arrangements of protein monomers (see section 2.6 and Table S1 in the SI for number 
and length of simulations). A protein–protein contact analysis on these simulations confirms that the enhanc-
ing effect of DHA on protein aggregation is not markedly driven by the initial configuration of protomers(see 
Tables S1 and S2 as well as Fig. S10). As shown in the SI (Figs S11 and S12), the DHA effect is also present when 
simulating receptors of the same protein type. Details about the preferred homo- and heterodimer interfaces 
formed can be found in the SI (section 2.2). In brief, as previously described in similar CG-MD studies50,53, 
oligomerisation of A2A and dopamine D2 receptors predominantly occurs via TM1, TM2 and helix 8 or TM3, 
TM4 and TM5 surfaces.
DHA increases lateral diffusion rates. To study the effect of DHA on protein diffusion, we performed a 
new set of CG-MD simulations based on single monomers (i.e. A2A or D2) (see Table S1 for number and length 
of simulations) and extracted protein diffusion coefficients (see section 1.2.1 in the SI). As shown in Fig. S13, 
proteins display higher mean squared displacements (MSDs) when diffusing in the more fluid environment of a 
healthy-like (DHA-enriched) membrane than in diseased-like (low DHA) membranes. Specifically, A2A and D2 
receptors simulated in healthy-like membranes display an average diffusion coefficient of 4.8 ± 1.3 × 10−9 cm2/s 
and 4.6 ± 1.0 × 10−9 cm2/s, respectively. In contrast, when simulated in diseased-like membranes, A2A and D2 
receptors show a slower diffusion of 1.8 ± 0.6 × 10−9 cm2/s and 2.2 ± 0.6 × 10−9 cm2/s, respectively. Similarly, the 
calculated protein rotational motion is slower in diseased-like membranes (Fig. S14), a trend particularly evident 
for the D2 receptor. However, the effect of lipid composition on lipid diffusion are not markedly different across 
Figure 4. Ratios of A2A receptor–lipid contacts of unsaturated (SDPC and POPC) and saturated (SAT) lipid 
tails during the all-atom simulation. 
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systems (Table S5). Therefore, while diseased-like (low DHA) environments slows down protein diffusion by a 
factor of 2–3 respect healthy-like (high DHA) one, differences in lipid diffusion coefficients are just within the 
error range.
Figure 5. Final snapshots of healthy- and diseased-like systems after 60 μs of CG-MD simulation. Left and 
right columns display 3 replicas of healthy- (high DHA, left) and diseased-like (low DHA, right) systems. A2A 
and D2 helices are depicted in red and blue cartoons, respectively. Dark grey spheres correspond to all membrane 
lipids except for SDPC molecules depicted in yellow surface. Water and ions are not shown for clarity.
www.nature.com/scientificreports/
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In general, the simulation data suggest that higher levels of DHA allow proteins to travel longer distances and 
sample a higher number of potential dimerisation interfaces due to enhanced translational and rotational diffu-
sion, respectively. As a result of a faster diffusion, proteins could aggregate more rapidly in healthy-like model 
membranes (Fig. 6, left), where we find that nearly all monomeric structures (blue) disappear within 5–10 μ s, 
making room for dimers (yellow), trimers (orange) or even higher-order arrangements such as tetramers (red). 
In contrast, in diseased-like systems (Fig. 6, right), most of the monomeric structures need 15–20 μ s to form 
higher-order structures.
To further study the dynamics of more crowded environments, we also calculated lipid diffusion coefficients 
in the multi-protein systems. Whereas lipid diffusion was not systematically affected by the presence of DHA in 
diluted conditions (non-crowded), lipids diffuse 10–40% faster in high-DHA membranes under protein-crowded 
conditions (see Table 2 and Fig. S15). In agreement with a recent study on lipid diffusion in protein-crowded envi-
ronments54, lipid diffusion coefficients are, however, lower than those calculated from non-crowded simulations 
(see Table S5). It is worth noting that out of the six lipid species, SDPC displays the lowest diffusion coefficient in 
both healthy- and diseased-like systems (Table 2). Such low diffusion is consistent with the fact that SDPC is the 
most common lipid of the protein-solvating lipid shell (Figs 2 and S4). Moreover, practically all SDPC is bound 
to the receptors in diseased-like systems (i.e. low DHA) whereas a fraction of SDPC is freely diffusing in healthy 
like systems (i.e. high DHA) (Fig. 5). Hence, a plausible explanation for the low diffusion values shown by SDPC 
is that the high number of DHA–protein interactions slows down the diffusion of the bound SDPC, in agreement 
Figure 6. Time-dependence of protein aggregation in CG-MD simulations. Data are shown for healthy-like 
(i.e. high DHA, left) and diseased-like (low DHA, right) systems. Each cell represents one of the three replicas 
and each line in the plots corresponds to an individual receptor. The colour code reflects the number of contacts 
per protomer. Corresponding data for the short (16 μ s) systems is shown in Fig. S9.
Figure 7. Time evolution of the mean number of protein–protein contacts per protomer in the set of 
shorter simulations. ‘Healthy’ and ‘Diseased’ refer to healthy-like (high DHA) and diseased-like (low DHA) 
model membranes. Average values are shown by dashed lines.
www.nature.com/scientificreports/
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with previous work55. The comparison of lateral diffusion values obtained from these CG-MD simulations with 
experiments is discussed in section 2.17 of the SI.
DHA–DHA interactions and lipid phase-segregation contribute to increase the oligomerisa-
tion rate. To better understand whether other factors besides increased lateral mixing contribute to the 
higher oligomerisation rate observed in healthy-like (i.e. high DHA) membranes, we performed further CG-MD 
simulations. We built an additional system using a simplified membrane composition even richer in DHA. 
Namely, we embedded 9 A2A and 9 D2 protomers in a ternary mixture made of 1-palmitoyl-2-oleoyl-sn-glycero-3
-phosphocholine (POPC): 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphatidylethanolamine (SDPE): cho-
lesterol (30%:50%:20%) and simulated 3 replicas for 120 μ s (see section 1.1.3 and Tables S1 and S3b in the SI). It 
is worth noting that in this system DHA accounts for up to ~31% of the lipid tails. Due to the lack of saturated 
lipids (DSPC, DPPC or SM) this system showed ~3 times faster diffusion values when compared to the diffu-
sion results measured in conventional healthy-like systems. Thus, we obtained values of 8.1 ± 0.7 × 10−8 cm2/s, 
8.1 ± 0.6 × 10−8 cm2/s and 12.4 ± 0.7 × 10−8 cm2/s for POPC, SDPE and cholesterol, respectively. However, faster 
lipid diffusion rates did not correlate with higher protein oligomerisation rates (see Fig. S16). Actually, in the 
membrane with very high DHA content most of the protein monomers take longer to engage in protein–protein 
interactions and many of them remain in a monomeric state after 120 μ s. This result indicates that despite DHA 
concentration does modulate the mobility of membrane components, a higher mobility does not necessarily lead 
to an increased oligomerisation rate.
Moreover, to ascertain whether lipid-segregation forces contribute to the DHA effect, we studied the tendency 
of healthy-like membranes to undergo phase separation into DHA-enriched and DHA-depleted regions in the 
absence of proteins. Thus, we built a protein-free version of the healthy-like system (see Table S3a) and simulated 
it for 40 μ s (see Table S1 for number and length of simulations). The ability of this lipid mixture to separate into 
domains could explain why DHA-coated receptors prefer to remain in close contact with each other. As shown 
in Fig. S17, healthy-like systems tend to separate into DHA-enriched and DHA-depleted domains. However, we 
do not observe any sharp domain boundary typically observed in phase separation studies using the Martini 
force field56. Instead, our simulations show a partial phase separation potentially induced by the hybrid nature of 
SDPC. We validated this observation by computing the time evolution of the contact fraction between saturated 
and unsaturated lipids as calculated in ref. 57 (see Fig. S18). Therefore, a partial phase-separation effect drives 
DHA-coated receptors to come closer to each other quicker than proteins where a DHA shell is not present or not 
entirely formed. Likewise, protein concentration will tend to be higher in DHA-enriched domains thus maximiz-
ing protein–protein interactions. Phase separation effects are absent in the system with very high DHA content.
In addition to limiting the accessible area of the receptors through partial phase separation, the favourable 
interaction between DHA chains likely contributes to the increased oligomerisation kinetics in high-DHA sys-
tems. DHA shells seem to increase the effective dimerisation radius of DHA-coated receptors when compared to 
uncoated ones. Thus, DHA–DHA interactions would enhance protein oligomerisation by allowing DHA-coated 
receptors to ‘sense’ each other at longer distances and eventually bringing receptors closer (see Movie S1 and sec-
tion S2.1). We quantified this effect by assessing the receptor–receptor distance over time. Characteristic exam-
ples of these plots are shown in Fig. S19. In diseased-like membranes (i.e. low DHA), receptors can remain at 
an intermolecular distance of approximately 5 nm for several μ s without effectively aggregating. In contrast, in 
healthy-like membranes (i.e. high DHA) effective oligomerisation consolidates as soon as protomers get closer 
than 5.5–6 nm. Interestingly, this value corresponds to the sum of the cut-off distance employed to define a pro-
tein–protein contact (4.2 nm) plus the widths of the two SDPC shells in the membrane plane (2 times approxi-
mately 0.8–0.9 nm).
Finally, we assured that the observed accelerated effect on receptor oligomerisation is not an artefact of over-
estimated protein–protein interactions of the Martini model58 and the use of Martini version 2.1 instead of the 
recently released version 2.259. We verified that neither scaling down the protein–protein interactions nor using 
the latest version of the force fields affects this conclusion (see Section 2.15 and Table S1 in the SI for number and 
length of simulations).
Overall, these results indicate that favourable DHA–DHA interactions and lipid phase-segregation forces con-
tribute along with increased lateral mixing to the effect of DHA on protein aggregation.
Lipid Healthy Diseased
CHOL 3.4 ± 0.2 2.6 ± 0.2
SM 2.7 ± 0.2 2.5 ± 0.2
DPPC 2.9 ± 0.4 2.5 ± 0.2
DSPC 2.9 ± 0.2 2.4 ± 0.1
DOPC 2.9 ± 0.3 2.4 ± 0.1
SDPC 2.1 ± 0.2 1.3 ± 0.1
Table 2.  Diffusion coefficients of lipids extracted from the multi-protein CG-MD systems. ‘Healthy’ 
and ‘Diseased’ refer to healthy-like (high DHA) and diseased-like (low DHA) model membranes. Values are 
reported in 10−8 cm2/s ± the error estimate. The calculation of error estimates is described in section 1.2.1 of the 
SI.
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Discussion
Experimental evidence suggests that both GPCR oligomerisation22–25 and DHA4–6 play a relevant role in brain 
functioning. In this study we report for the first time a molecular link between membrane levels of DHA and the 
oligomerisation rate of A2A and D2 receptors, which could have important implications for the treatment of major 
psychiatric disorders.
We have used molecular simulation methods and laboratory experiments to assess the effect of DHA levels 
on the formation of A2A − D2 oligomers. CG-MD simulations indicate that the kinetics of adenosine A2A and 
dopamine D2 aggregation is modulated by membrane DHA levels. Specifically, low levels of DHA significantly 
diminished the ability of A2A and D2 receptors to engage in protein–protein contacts in the microsecond time 
scale probed by these simulations. To further study the impact of low and high DHA levels on GPCR oligomeri-
sation, we used a classical experimental approach, namely BRET measurements in living cells. It is important to 
note that the temporal sensitivity of the BRET technique is around the millisecond time scale, thus reaching far 
beyond our CG-MD simulations (i.e. microseconds). Accordingly, we employed BRET determinations to mon-
itor DHA-mediated changes upon equilibrium conditions through end-point experiments. These experiments 
show that the level of membrane DHA does not affect the steady-state intensity of A2A − D2 oligomerisation 
(Fig. 1), thus suggesting a purely kinetic effect of membrane DHA on receptor oligomerisation. While DHA has 
an important role in the speed of oligomer formation in CG-MD simulations, higher levels of this fatty acid does 
not seem to impact the amount of oligomers in equilibrium. Nevertheless, caution is needed when interpreting 
results as the BRET approach might not be sufficiently sensitive to pick up a DHA-induced alteration on the equi-
librium state of receptor oligomerisation. New imaging-based approaches with higher temporal resolution (e.g. 
double-receptor tracking by super resolution fluorescence microscopy) should, however, be implemented in the 
near future to solve the sensitivity issue revolving around the BRET approach.
In addition, this study provides insights into a mechanism that could underlie the kinetic effect of DHA on 
receptor oligomerisation. We find that membrane DHA levels modulate the diffusion of membrane lipids (Table 2, 
Table S5 and Fig. S15 in the SI), the diffusion of receptors (Table S5 and Figs S13 and S14) and, ultimately, the rate 
of spontaneous protein–protein interactions (Fig. 6). Thus, A2A and D2 receptors can travel longer distances and 
sample a higher number of potential dimerisation interfaces in high-DHA membranes. Unexpectedly, control 
simulations using a very high DHA content show drastically higher values of lipid diffusion which does not corre-
late with increased oligomerisation rates (Fig. S16). This suggests that diffusion rates are not the only contributing 
factor to DHA-induced effect on protein oligomerisation. Interestingly, the formation of a DHA shell around 
the receptors seems to play a key role in this effect (see Movie S1). The presence of this solvation shell (see Figs 2 
and S4 as well as Fig. 4) in both CG-MD and all-atom MD simulations is in line with previous experiments60 and 
simulations19 showing a preferential aggregation of DHA around rhodopsin. The high affinity between DHA and 
receptors is based on the tremendous flexibility of DHA tails when compared to saturated and mono-unsaturated 
ones61. As demonstrated by Grossfield et al.20, the nature of the spontaneous solvation of GPCRs by DHA relies on 
the lower entropic cost paid by polyunsaturated tails like DHA to interact with the protein.
We propose that this shell is involved in two fundamental properties of the enhancing effect of DHA on pro-
tein oligomerisation. Firstly, control simulations demonstrate that DHA can induce partial phase segregation 
(Figs S17 and S18), in agreement with previous experiments9. The low affinity between DHA and the rest of mem-
brane lipids including cholesterol is a major entropic factor leading to phase segregation and ultimately to the 
enrichment of DHA around receptors, as previously shown for rhodopsin62. In this scenario, receptors covered 
by DHA will partition into DHA-enriched domains. This reduces the effective sampling area of receptors within 
the membrane thus increasing the number of receptor–receptor encounters. Secondly, DHA shells enhance the 
ability of DHA-coated receptors to engage in protein–protein contacts by increasing its effective oligomerisation 
radius. As a result, protein oligomerisation does not necessarily need direct protein–protein contacts to occur 
but it is rather initiated as two DHA shells come closer due to the high affinity between DHA tails (see Movie S1 
and Fig. S18). Both effects (i.e. phase segregation and favoured interactions between DHA-coated receptors) are 
negligible when DHA is present in too high concentrations. In this scenario, no membrane domains are formed 
and DHA-coated receptors are not particularly driven to engage in protein–protein contacts as they equally inter-
act with the DHA-enriched membrane bulk. Overall, these results suggest that the role of DHA on receptor 
aggregation kinetics is beyond increasing membrane fluidity but rather based on both an increased lateral mobil-
ity of receptors and a favoured interaction between proteins fostered by the presence of a DHA solvation shell. 
Ultimately, a relevant question arises about how this mechanism translates into a specific receptor signalling 
response. As postulated by Noé and co-workers63, the formation of specific supramolecular architectures (i.e. 
tracks of rhodopsin dimers) does not seem to accelerate the rate of G protein binding to rhodopsin. However, 
these oligomers are thought to create a kinetic trap for Gt molecules controlling the rate of rhodopsin activation 
thus modulating receptor signalling64. In this context, it tempting to speculate that a lack of DHA (i.e. as observed 
in certain neuropsychiatric disorders) could impair the efficiency of this kinetic trap by diminishing the forma-
tion rate of specific signalling platforms such as A2A and dopamine D2 receptor oligomers.
In conclusion, our results suggest that higher levels of DHA accelerate protein aggregation and highlights the 
role of kinetics in modulating A2A and D2 oligomerisation. Through extensive simulations on a wide set of model 
systems, we have been able to postulate a mechanism behind the influence of membrane DHA on the oligomer-
isation kinetics of A2A and D2 receptors. These results provide an important advance in understanding the inter-
play between membrane lipids and key transmembrane proteins like GPCRs, a topic of current special interest in 
biochemistry and biophysics. Importantly, these results could partly underlie the neuroprotective properties of 
DHA supplementation reported previously in animal studies5,12. In particular, the observed kinetic effect could 
have an impact in the response rate to endogenous neurotransmitters in patients with an altered DHA membrane 
content. In that case, restoring membrane DHA levels in individuals with schizophrenia or Parkinson’s disease 
could become a strategy to improve the impaired crosstalk of the A2A − D2 oligomer observed in these disorders23. 
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Our findings create new opportunities to explore the use of membrane lipids as a therapeutic tool for major neu-
ropsychiatric conditions where A2A and D2 oligomers have been shown to have particular importance.
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